12:00 AM
 | 
May 29, 2001
 |  BioCentury  |  Strategy

Metabolics bet pays off for Isis

Although Isis Pharmaceuticals Inc. has invested heavily in its antisense programs in cancer, infectious diseases and autoimmune disorders, a minor bet on antisense compounds for metabolic disorders has yielded a payoff in just 18 months.

Last week, ISIP granted Merck & Co. Inc. (MRK, Whitehouse Station, N.J.) an exclusive license to a preclinical antisense compound for Type II diabetes and obesity. The compound, ISIS 113715, is...

Read the full 329 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >